Experiment Number: 96003-02 P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Type: 14-DAY

Route: GAVAGE

CAS Number: 106-95-6

Species/Strain: Mouse/C57BL/6

C Number: C96003

Lock Date: 01/21/1999

Cage Range: All

Date Range: All

Reasons For Removal:

Removal Date Range: All

Treatment Groups: All

Study Gender: Both

PWG Approval Date NONE

Date Report Requested: 10/21/2014 **Time Report Requested:** 06:17:01

First Dose M/F: NA / NA

Lab: MBA

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Allyl bromide CAS Number: 106-95-6

Date Report Requested: 10/21/2014 Time Report Requested: 06:17:01 First Dose M/F: NA / NA

Lab: MBA

Species/Strain: Mouse/C57BL/6

Experiment Number: 96003-02

Test Type: 14-DAY

Route: GAVAGE

C57BL/6 Mouse MALE	VEHICLE CONTROL	7.5 MG/KG	15 MG/KG	30 MG/KG	60 MG/KG	120 MG/KG
Disposition Summary						
Animals Initially In Study	5	5	5	5	5	5
Early Deaths						
Moribund Sacrifice						1
Natural Death						2
Survivors						
Terminal Sacrifice	5	5	5	5	5	2
Animals Examined Microscopically	5	5	5	5	5	5
ALIMENTARY SYSTEM						
Stomach, Forestomach	(5)	(5)	(5)	(5)	(5)	(5)
Epithelium, Degeneration, Diffuse		1 (20%)	1 (20%)	1 (20%)	1 (20%)	
Epithelium, Degeneration, Focal			2 (40%)	2 (40%)		
Epithelium, Hyperplasia, Diffuse			1 (20%)	2 (40%)		1 (20%)
Epithelium, Hyperplasia, Focal			2 (40%)	1 (20%)	4 (80%)	2 (40%)
Epithelium, Inflammation, Chronic Active, Focal			1 (20%)	3 (60%)	1 (20%)	
Epithelium, Muscularis, Inflammation, Chronic Active, Diffuse						1 (20%)
Epithelium, Muscularis, Serosa, Inflammation, Chronic Active, Diffuse					1 (20%)	
Epithelium, Muscularis, Serosa, Inflammation, Chronic Active, Focal					2 (40%)	
Epithelium, Muscularis, Serosa, Ulcer, Diffuse						2 (40%)
Epithelium, Muscularis, Serosa, Ulcer, Focal					2 (40%)	1 (20%)
Epithelium, Ulcer, Focal						1 (20%)
Hyperkeratosis, Diffuse			1 (20%)	2 (40%)	2 (40%)	2 (40%)
Hyperkeratosis, Focal			2 (40%)	1 (20%)	3 (60%)	1 (20%)
Muscularis, Serosa, Inflammation, Chronic Active, Diffuse						1 (20%)

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Type: 14-DAY **Route:** GAVAGE

Test Compound: Allyl bromide

Time Report Requested: 06:17:01 First Dose M/F: NA / NA

Date Report Requested: 10/21/2014

Route: GAVAGE CAS Number: 106-95-6
Species/Strain: Mouse/C57BL/6

Lab: MBA

C57BL/6 Mouse MALE	VEHICLE CONTROL	7.5 MG/KG	15 MG/KG	30 MG/KG	60 MG/KG	120 MG/KG
Muscularis, Serosa, Inflammation, Chronic Active, Focal						1 (20%)
Stomach, Glandular	(5)	(5)	(5)	(5)	(5)	(4)
Epithelium, Muscularis, Inflammation, Chronic Active, Focal						1 (25%)
Epithelium, Necrosis, Focal						2 (50%)
CARDIOVASCULAR SYSTEM None						
ENDOCRINE SYSTEM None						
GENERAL BODY SYSTEM None						
GENITAL SYSTEM None						
HEMATOPOIETIC SYSTEM Spleen Pigmentation, Focal	(0)	(0)	(1) 1 (100%)	(0)	(0)	(0)
NTEGUMENTARY SYSTEM None						
//USCULOSKELETAL SYSTEM None						
NERVOUS SYSTEM None						
RESPIRATORY SYSTEM						
Nose	(0)	(0)	(0)	(1)	(0)	(0)

SPECIAL SENSES SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Species/Strain: Mouse/C57BL/6

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Type: 14-DAY **Route:** GAVAGE

Test Compound: Allyl bromide **CAS Number:** 106-95-6

Date Report Requested: 10/21/2014
Time Report Requested: 06:17:01

First Dose M/F: NA / NA

Lab: MBA

C57BL/6 Mouse MALE VEHICLE CONTROL 7.5 MG/KG 15 MG/KG 30 MG/KG 60 MG/KG 120 MG/KG
None

URINARY SYSTEM

None

END OF MALE DATA

Species/Strain: Mouse/C57BL/6

Test Type: 14-DAY

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Allyl bromide CAS Number: 106-95-6

Date Report Requested: 10/21/2014
Time Report Requested: 06:17:01

First Dose M/F: NA / NA

Lab: MBA

C57BL/6 Mouse FEMALE	VEHICLE CONTROL	7.5 MG/KG	15 MG/KG	30 MG/KG	60 MG/KG	120 MG/K
Disposition Summary						
Animals Initially In Study	5	5	5	5	5	5
Early Deaths						
Survivors						
Terminal Sacrifice	5	5	5	5	5	5
Animals Examined Microscopically	5	5	5	5	5	5
ALIMENTARY SYSTEM						
Stomach, Forestomach	(5)	(5)	(5)	(5)	(5)	(5)
Epithelium, Degeneration, Focal		1 (20%)	4 (80%)	5 (100%)		
Epithelium, Hyperplasia, Focal		3 (60%)	4 (80%)	5 (100%)	5 (100%)	5 (100%)
Epithelium, Inflammation, Chronic Active, Focal				2 (40%)		
Epithelium, Muscularis, Inflammation, Chronic Active, Focal					1 (20%)	
Epithelium, Muscularis, Serosa, Inflammation, Chronic Active, Focal					4 (80%)	
Epithelium, Muscularis, Serosa, Ulcer, Focal					3 (60%)	5 (100%)
Epithelium, Necrosis, Focal					2 (40%)	
Hyperkeratosis, Diffuse		2 (40%)		2 (40%)		1 (20%)
Hyperkeratosis, Focal					5 (100%)	4 (80%)
Stomach, Glandular	(5)	(5)	(5)	(5)	(5)	(5)
CARDIOVASCULAR SYSTEM						
None						
ENDOCRINE SYSTEM						
None						
GENERAL BODY SYSTEM						

None

GENITAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Type: 14-DAY **Route:** GAVAGE

VAGE

Species/Strain: Mouse/C57BL/6

Test Compound: Allyl bromide CAS Number: 106-95-6

Date Report Requested: 10/21/2014 Time Report Requested: 06:17:01

First Dose M/F: NA / NA

Lab: MBA

C57BL/6 Mouse FEMALE	VEHICLE CONTROL	7.5 MG/KG	15 MG/KG	30 MG/KG	60 MG/KG	120 MG/KG
None						
HEMATOPOIETIC SYSTEM						
Lymph Node	(0)	(0)	(0)	(0)	(2)	(3)
Mediastinal, Hyperplasia, Lymphoid, Diffuse					2 (100%)	3 (100%)
Spleen	(0)	(1)	(1)	(1)	(1)	(0)
Pigmentation, Focal		1 (100%)	1 (100%)	1 (100%)	1 (100%)	
INTEGUMENTARY SYSTEM						
None						,
MUSCULOSKELETAL SYSTEM						
None						
NERVOUS SYSTEM						
None						
RESPIRATORY SYSTEM						
None						
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney	(0)	(1)	(0)	(0)	(0)	(0)
Cyst, Diffuse	()	1 (100%)	` '	` '	()	()

^{**} END OF REPORT **

a - Number of animals examined microscopically at site and number of animals with lesion